5.56

4.12% 0.22

Aclaris Therapeutics Inc (ACRS)

Overview News Price History Option Chain Financials Why ACRS Down? Discussions Forecast

Aclaris Therapeutics Inc stock is traded at $5.56, with a volume of 1.94M. It is up +4.12% in the last 24 hours and up +20.09% over the past month. Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.

Previous Close:

$5.34

Open:

$5.36

24h Volume:

1.94M

Relative Volume:

1.25

Market Cap:

$776.53M

Revenue:

$8.37M

Net Income/Loss:

$-69.66M

P/E Ratio:

-9.9215

EPS:

-0.5604

Net Cash Flow:

$-51.45M

1W Performance:

+13.24%

1M Performance:

+20.09%

6M Performance:

+93.06%

1Y Performance:

+283.45%

1-Day Range:

$5.325

$5.58

1-Week Range:

$4.80

$5.69

52-Week Range:

$1.435

$5.69

Aclaris Therapeutics Inc Stock (ACRS) Company Profile

Name

Aclaris Therapeutics Inc

Sector

Healthcare (1098)

Industry

Biotechnology (615)

Phone

484-324-7933

Address

701 LEE ROAD, WAYNE, PA

Employee

Twitter

@aclaristx

Next Earnings Date

2026-08-06

Latest SEC Filings

ACRS's Discussions on Twitter

Compare ACRS vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ACRS Aclaris Therapeutics Inc	5.56	738.82M	8.37M	-69.66M	-51.45M	-0.5604
VRTX Vertex Pharmaceuticals Inc	528.04	126.07B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	654.27	65.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	939.68	57.70B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	312.78	40.19B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	189.24	39.82B	742.00K	-1.37B	-1.07B	-7.0731

Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-16-26	Initiated	Oppenheimer	Outperform
Jul-10-25	Resumed	Piper Sandler	Overweight
May-28-25	Initiated	Wedbush	Outperform
Mar-18-25	Resumed	Cantor Fitzgerald	Overweight
Dec-23-24	Upgrade	H.C. Wainwright	Neutral → Buy
Nov-20-24	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Nov-19-24	Upgrade	BTIG Research	Neutral → Buy
Nov-19-24	Upgrade	Jefferies	Hold → Buy
Nov-19-24	Upgrade	Leerink Partners	Market Perform → Outperform
Nov-18-24	Upgrade	Piper Sandler	Neutral → Overweight
Jan-22-24	Downgrade	H.C. Wainwright	Buy → Neutral
Nov-13-23	Downgrade	William Blair	Outperform → Mkt Perform
Oct-03-23	Initiated	Evercore ISI	Outperform
Dec-14-22	Initiated	Stifel	Buy
Dec-01-22	Initiated	Goldman	Buy
Oct-06-22	Initiated	BTIG Research	Buy
Jul-23-21	Resumed	Jefferies	Buy
Jun-15-21	Initiated	Piper Sandler	Overweight
Apr-21-21	Initiated	H.C. Wainwright	Buy
Oct-22-19	Upgrade	SVB Leerink	Mkt Perform → Outperform
Sep-06-19	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Jun-27-19	Downgrade	SVB Leerink	Outperform → Mkt Perform
May-06-19	Initiated	SVB Leerink	Outperform
Mar-28-18	Resumed	Leerink Partners	Outperform
Feb-09-18	Initiated	Guggenheim	Buy
Jun-16-17	Initiated	Cantor Fitzgerald	Overweight
Nov-29-16	Initiated	Leerink Partners	Outperform
Sep-30-16	Initiated	JMP Securities	Mkt Outperform
Jun-10-16	Initiated	Guggenheim	Buy
Nov-02-15	Initiated	Citigroup	Buy
Nov-02-15	Initiated	Jefferies	Buy

View All

Aclaris Therapeutics Inc Stock (ACRS) Latest News

Jul 01, 2026

Strength Seen in Aclaris (ACRS): Can Its 5.4% Jump Turn into More Strength? - Yahoo Finance

Jul 01, 2026

Jun 29, 2026

Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com

Jun 29, 2026

Aclaris Therapeutics, Inc.(NasdaqGS: ACRS) added to Russell 2500 Growth Benchmark - marketscreener.com

Jun 29, 2026

Aclaris Therapeutics, Inc.(NasdaqGS: ACRS) added to Russell 2000 Growth Benchmark - marketscreener.com

Jun 29, 2026

Aclaris Therapeutics, Inc.(NasdaqGS: ACRS) added to Russell 3000E Growth Benchmark - marketscreener.com

Jun 29, 2026

Jun 28, 2026

Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) added to Russell Microcap Growth Benchmark Index - marketscreener.com

Jun 28, 2026

Price to sales forward of Aclaris Therapeutics, Inc. – NASDAQ:ACRS - TradingView

Jun 28, 2026

Jun 27, 2026

Price to book forward of Aclaris Therapeutics, Inc. – NASDAQ:ACRS - TradingView

Jun 27, 2026

Enterprise value to EBIT forward of Aclaris Therapeutics, Inc. – DUS:8AT - TradingView

Jun 27, 2026

Price to earnings forward of Aclaris Therapeutics, Inc. – NASDAQ:ACRS - TradingView

Jun 27, 2026

Price to earnings forward of Aclaris Therapeutics, Inc. – DUS:8AT - TradingView

Jun 27, 2026

Jun 26, 2026

Enterprise value to EBITDA forward of Aclaris Therapeutics, Inc. – NASDAQ:ACRS - TradingView

Jun 26, 2026

We Think Aclaris Therapeutics (NASDAQ:ACRS) Can Afford To Drive Business Growth - Moomoo

Jun 23, 2026